Rosuvastatin Effective in Primary Prevention in Intermediate-Risk Population瑞舒伐他汀对中危人群一级预防有效

A randomized study revealed that 10 mg of rosuvastatin per day with or without antihypertensive significantly lowered risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. The study included 12,705 participants in 21 countries with median follow-up of 5.6 years. The overall mean low-density lipoprotein cholesterol level was 26.5% lower in the rosuvastatin group than in the placebo group. Risks of the first and second coprimary outcomes reduced about 25%. The results were consistent in subgroups. There was an excess of cataract surgery and muscle symptoms but no excess of diabetes or cancers in the rosuvastatin group. Source: http://www.nejm.org/

一项随机研究表明，与安慰剂相比，每天瑞舒伐他汀10毫克，显著降低多种族无心血管病中危人群心血管事件的风险，无论合用降压药与否。这项研究包括21个国家的12705名参与者，平均随访5.6 年。总平均低密度脂蛋白胆固醇水平瑞舒伐他汀组比安慰剂组低26.5％。第一和第二综合主要结果的风险降低25％左右。各亚组结果一致。瑞舒伐他汀组白内障手术和肌肉症状较多，而非糖尿病或癌症。来源：http://www.nejm.org/